New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
07:50 EDTGWPHGW Pharmaceuticals shares attractive ahead of data, says Leerink
After meeting with management, Leerink says is continue to view shares of GW Pharmaceuticals as attractive here ahead of additional Epidiolex data readouts and the commencement of pivotal trials in the second half of 2014. The firm reiterates an Outperform rating on the stock with a $110 price target.
News For GWPH From The Last 14 Days
Check below for free stories on GWPH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 4, 2014
08:23 EDTGWPHGW Pharmaceuticals mentioned positively at Leerink
Leerink says it has increased confidence in GW Pharmaceuticals' cannabinoid platform after analyzing the clinical potential of GWP42003 for Ulcerative Colitis. The firm believes GWP42003 is being largely overlooked by investors, creating low expectations into the Phase II data. Leerink has an Outperform rating on GW with a $110 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use